Monitoring of minimal residual disease (MRD) has become routine clinical practice in
frontline treatment of virtually all childhood acute lymphoblastic leukemia (ALL) and in many …

Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL)
results in high cure rates in pediatric patients but is suboptimal in the treatment of adult …

Importance Minimal residual disease (MRD) refers to the presence of disease in cases
deemed to be in complete remission by conventional pathologic analysis. Assessing the …

Purpose Few therapeutic options are available for patients with Philadelphia chromosome–
positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of …

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib
combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD …

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic
lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related …

Abstract Prognosis of Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in the
elderly has improved during the imatinib era. We investigated dasatinib, another potent …

Significant advances have been made in the last decade toward a better understanding of
the disease pathogenesis and the development of novel therapies that target specific …

Background Combination of chemotherapy with a tyrosine-kinase inhibitor is effective in the
treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia. Ponatinib is …

Acute lymphoblastic leukemia (ALL) is a disseminated malignancy of B-or T-lymphoblasts
which imposes a rapid and accurate diagnostic process to support an optimal risk-oriented …